The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
HainsworthJ.D., GroshW.W., BurnettL.S.Advanced ovarian cancer: Long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Int Med.1998; 108(2): 165–70.
2.
YoungR.C., ChabnerB.A., HubbardS.P.Advanced ovarian adenocarcinoma: A prospective clinical trial of melphalan (L-PAM) versus combination therapy. New Engl J Med.1978; 299(23): 1261–6.
3.
ManettaA., MacNeillC., LyterJ.A.Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine). Cancer Treatment Rev.1991; 18(suppl A): 23–9.
BonomiP.D., MladineoJ., MorrinB.Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents. Cancer Treatment Reports.1979; 63(1): 137–8.
8.
RoseP.G., BlessingJ.A., ArseneauJ.Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Gynecol Oncol.1996; 62(1): 100–2.
9.
MooreD.H., FowlerW.C., JonesC.P.Hexamethylme-lamine chemotherapy for persistent or recurrent epithelial ovarian cancer. Am J Obstet Gynecol.1991; 155(3): 573–6.
10.
DrelichmanA., BrownleeR., Al-SarrafM.Phase II study of hexamethylmelamine for disseminated prostatic carcinoma. Cancer Clin Trials.1981; 4(3): 309–12.
11.
CobleighM.A., VogelC.L., TripathyD.Efficacy and safety of Herceptin (Humanized Anti-HER2 Antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proceed Am Soc Clin Oncol.1998; 17: 97a (Abstract 376).
12.
SalmonD., Lowland-JonesB., ShakS.Addition of Herceptin (Humanized Anti-HER2 Antibody) to first line chemotherapy of HER2 overexpressing metastatic breast cancer (HER2+MBC) markedly increases anticancer activity: A randomized, multinational controlled Phase III trial. Proceed Am Soc Clin Oncol.1998; 17: 98a (Abstract 377).
13.
PegramM.D., LiptonA., HayesD.F.Phase II study of receptor-enhanced chemosensitivity using recombinant
